The monoaminergic pathways and inhibition of monoamine transporters interfere with the antidepressive-like behavior of ketamine
IBRO Reports June 13, 2018 Glauce Socorro de Barros Viana, Cecilia Coelho Xavier, Eduardo Mulato Do Vale et al. 10 citations
Ketamine (KET), a NMDA receptor antagonist, has been studied for its rapid and efficacious antidepressant effect, even for the treatment-resistant depression. Although depression is a major cause of disability worldwide, the treatment can be feasible, affordable and cost-effective, decreasing the population health burden. We evaluated the antidepressive-like effects of KET and its actions on...